These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20337926)

  • 1. Flexible and individualized treatment to achieve sustained viral response for recurrent hepatitis C in liver transplant recipients.
    Lee WC; Wu TJ; Chou HS; Lee CF; Chan KM; Cheng SS
    J Viral Hepat; 2010 Nov; 17(11):770-7. PubMed ID: 20337926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.
    Bizollon T; Palazzo U; Ducerf C; Chevallier M; Elliott M; Baulieux J; Pouyet M; Trepo C
    Hepatology; 1997 Aug; 26(2):500-4. PubMed ID: 9252166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation.
    Giostra E; Kullak-Ublick GA; Keller W; Fried R; Vanlemmens C; Kraehenbuhl S; Locher S; Egger HP; Clavien PA; Hadengue A; Mentha G; Morel P; Negro F
    Transpl Int; 2004 May; 17(4):169-76. PubMed ID: 15060764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
    Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
    Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral therapy for hepatitis C virus recurrence following liver transplantation: long-term results from a single center experience.
    Burra P; Targhetta S; Pevere S; Boninsegna S; Guido M; Canova D; Brolese A; Masier A; D'Aloiso C; Germani G; Tomat S; Fagiuoli S
    Transplant Proc; 2006 May; 38(4):1127-30. PubMed ID: 16757285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence.
    Sharma P; Marrero JA; Fontana RJ; Greenson JK; Conjeevaram H; Su GL; Askari F; Sullivan P; Lok AS
    Liver Transpl; 2007 Aug; 13(8):1100-8. PubMed ID: 17377914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin.
    Ahmad J; Dodson SF; Demetris AJ; Fung JJ; Shakil AO
    Liver Transpl; 2001 Oct; 7(10):863-9. PubMed ID: 11679984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preemptive antiviral treatment for hepatitis C virus after living donor liver transplantation.
    Sugawara Y; Tamura S; Yamashiki N; Kaneko J; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N
    Transplant Proc; 2012 Apr; 44(3):791-3. PubMed ID: 22483497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
    Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study: longer duration of posttransplant hepatitis C virus therapy may increase the sustained response rate.
    Karasu Z; Akay S; Yilmaz F; Akarca U; Ersoz G; Gunsar F; Kilic M
    Transplant Proc; 2009 Nov; 41(9):3806-9. PubMed ID: 19917392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C.
    Shakil AO; McGuire B; Crippin J; Teperman L; Demetris AJ; Conjeevaram H; Gish R; Kwo P; Balan V; Wright TL; Brass C; Rakela J
    Hepatology; 2002 Nov; 36(5):1253-8. PubMed ID: 12395337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.
    Giannini EG; Basso M; Savarino V; Picciotto A
    Aliment Pharmacol Ther; 2010 Feb; 31(4):502-8. PubMed ID: 19925499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.
    Roche B; Sebagh M; Canfora ML; Antonini T; Roque-Afonso AM; Delvart V; Saliba F; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2008 Dec; 14(12):1766-77. PubMed ID: 19025933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study.
    Alberti AB; Belli LS; Airoldi A; de Carlis L; Rondinara G; Minola E; Vangeli M; Cernuschi A; D'Amico M; Forti D; Pinzello G
    Liver Transpl; 2001 Oct; 7(10):870-6. PubMed ID: 11679985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center.
    Testillano M; Fernandez JR; Suarez MJ; Gastaca M; Bustamante J; Pijoan JI; Montejo M; Valdivieso A; Ruiz P; Gonzalez J; Ortiz de Urbina J
    Transplant Proc; 2009 Apr; 41(3):1041-3. PubMed ID: 19376421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early prediction of hepatitis C virus (HCV) infection relapse in nonresponders to primary interferon therapy by means of HCV RNA whole-blood analysis.
    Watkins-Riedel T; Ferenci P; Steindl-Munda P; Gschwantler M; Mueller C; Woegerbauer M
    Clin Infect Dis; 2004 Dec; 39(12):1754-60. PubMed ID: 15578395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation.
    Riediger C; Berberat PO; Sauer P; Gotthardt D; Weiss KH; Mehrabi A; Merle U; Stremmel W; Encke J
    Nephrol Dial Transplant; 2007 Sep; 22 Suppl 8():viii37-viii46. PubMed ID: 17890261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.